Updox launches Pharmacy Connect at Cardinal Health’s 26th annual Retail Business Conference
DUBLIN, Ohio – Updox on Thursday introduced Pharmacy Connect, a care coordination suite for pharmacists, during Cardinal Health’s 26th annual Retail Business Conference. Pharmacy Connect offers retail and independent pharmacists an opportunity to enhance their ability to communicate and connect as the industry shifts to a value-based care model.
“In order to take advantage of new revenue opportunities, pharmacists have to use the same tools for communications, patient engagement and revenue growth that the rest of healthcare has been using for years," stated Michael Morgan, CEO Updox. "Without the ability to receive transitions of care, securely communicate and engage care teams, pharmacists risk losing revenue and putting themselves at a competitive disadvantage,” he said. “Direct messaging is a great place to start to ensure pharmacists have a level playing field as part of integrated care teams.”
Updox Pharmacy Connect is a care coordination suite that helps pharmacists exchange secure messages with physicians, receive transitions of care and engage patients to both take advantage of new revenue opportunities and lower costs. The suite provides an inbox allowing pharmacies to manage all types of communications, such as Direct secure messaging, paperless faxing and patient interactions via a portal where patients can send messages, complete forms and self-scheduling for vaccines, screenings or point of care testing.
More than 650,000 physicians already use Direct secure messaging to exchange clinical health data, Updox reported.
Former McKesson legal chief named chief compliance officer at Theranos
PALO ALTO, Calif. — A former McKesson legal chief on Thursday was one of two executives to join Theranos, the lab-testing company that earlier this month was sanctioned by the Centers for Medicare & Medicaid Services, the company announced.
The two new executives will lead the company’s regulatory, quality and compliance efforts and will report to Theranos CEO Elizabeth Holmes.
Daniel Guggenheim, a lawyer with deep background and leadership in health care compliance and regulations, was named chief compliance officer. And Dave Wurtz, who has nearly two decades experience in U.S. and international regulated industries, including the life sciences industry, was named VP regulatory and quality.
Meanwhile, the Theranos board of directors has created a Compliance and Quality Committee. It will oversee and advise the board and the company’s executive leadership on regulatory compliance and quality systems obligations.
Fabrizio Bonanni, who joined the board of directors in May, will chair the committee.
The Compliance and Quality Committee will oversee the company’s government compliance and regulatory obligations, including working directly with Wurtz and Guggenheim and further implementing and monitoring its compliance program.
The executive-level appointments of Wurtz and Guggenheim are effective immediately.
Guggenheim, as chief compliance officer, will lead day-to-day implementation and oversight of the company's compliance program, with an emphasis on maintaining and enhancing policies, procedures, training and monitoring mechanisms to promote compliance with all applicable state and federal regulations.
“Theranos is committed to meeting the highest standards in its compliance practices. I am eager to start to build on the foundation that Theranos is making to be a best-in-class health care company,” Guggenheim said.
Guggenheim has been assistant general counsel, regulatory law, at McKesson. He was the company’s chief regulatory and compliance counsel and senior counsel for its pharmaceutical division, addressing legal and regulatory matters on the sale of medical devices, the marketing and sale of drugs and health care information technology.
Guggenheim earned a law degree from the University of California at Berkeley.
Wurtz will be leading the strategy and implementation of Theranos’ pre- and post-market regulatory activities, including obtaining FDA clearances and approvals and marketing of new products and managing the regulatory affairs, medical device quality systems and clinical affairs teams.
He also will provide regulatory expertise to cross-functional teams for the development of new products.
Wurtz previously served as senior director of regulatory, quality and compliance at ThermoFisher Scientific. He managed multiple FDA inspections and was responsible for all pre- and post- market regulatory activities worldwide.
He earned a bachelor of science degree from the University of Illinois at Chicago.
The new executive appointments and the creation of the committee are the latest in a series of significant actions Theranos has taken to ensure that it meets the highest standards in its laboratories, medical products and operations, the company stated.
JAMA: Less than 3 generic rivals could lead to rising drug prices
CHICAGO – According to a recent study published in JAMA Internal Medicine, an analysis of FDA new drug and generic drug applications since the Hatch-Waxman Act took effect revealed that more than one-third of 210 novel therapeutics tracked had only three or fewer generic approvals.
The finding points to a potential gap in competition that has allowed prices for some generics to climb.
Conventional wisdom suggests the U.S. market for generics, accounting for more than 85% of prescriptions, was energized by the Hatch-Waxman Act of 1984. Indeed, generic competition of more than four generic manufacturers has been shown to drive down the cost of the brand-name drugs by roughly 60%.
Oncological medications and orphan-designated drugs were especially likely to lack generic alternatives, due to smaller markets and the probability of smaller profits. The researchers concluded that FDA might want to give priority to applications for drugs with three or fewer generic versions to avoid escalation in generic pricing.